Forecasted · Cooperative Agreement
Applied regulatory science research to evaluate and treat cardiotoxicity of oncology therapeutics
Food and Drug Administration, Department of Health and Human Services
Key facts
Copied from the official Grants.gov record. Last verified October 29, 2026.
- Program name
- Applied regulatory science research to evaluate and treat cardiotoxicity of oncology therapeutics
- Issuing agency
- Food and Drug Administration (Department of Health and Human Services)
- Opportunity number
- FOR-FD-25-015
- Funding type
- Cooperative Agreement
- Funding purpose
- Food and Nutrition, Consumer Protection, Agriculture
- Status
- Forecasted
- Application deadline
- Forecasted · no application dates yet
- Published award range
- Not published by the agency
- Expected number of awards
- 2
- Cost sharing or match required
- No
- Eligible applicants (official categories)
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Unrestricted (open to any type of entity, subject to any clarification in Additional Information on Eligibility)
- Relevant to
- Businesses and NonprofitsHow we determined this: Grants.gov lists eligibility as Unrestricted. Grants.gov eligibility includes small businesses or for-profit organizations. Grants.gov eligibility includes nonprofit organizations.
- Geographic restrictions
- None stated in structured data (federal opportunities are often nationwide). Check the eligibility details and full announcement for any limits.
- Assistance Listing (CFDA)
- 93.103
- Official source
- View on Grants.gov ↗
- Application URL
- www.grants.gov/search-results-detail/357261 ↗Apply through Grants.gov (Workspace) using the application package on the official listing, unless the full announcement names a different submission system.
- Source identifier
- Grants.gov opportunity ID 357261 · Funding opportunity number FOR-FD-25-015
- Posted
- November 20, 2024 · Source last updated November 20, 2024
- Last verified
- October 29, 2026 (against Grants.gov)
- Data completeness
- 75% of key fields published by the sourceNot published: published funding range, eligibility criteria text, application dates.
- Record confidence
- mediumforecast — dates and amounts are agency estimates.
Description (from the official listing)
The goal of this funding opportunity announcement is to support applied regulatory science research to evaluate and treat cardiotoxicity of oncology therapeutics. The main outcomes of this work will be publications and presentations; however, FDA staff anticipate substantial involvement in study design and reviewing interim deliverables to ensure that the studies develop practical approaches and solutions that have the potential to inform regulatory decision making in the future. We anticipate organizing regular calls with funded investigators to support the collaboration with FDA - reviewing annual reports would be insufficient to ensure that direction of the research addresses FDA's needs.OCE is interested in supporting research that improve the detection, monitoring and treatment of cardiotoxicity of oncology therapeutics.Specific areas of interest include:-Standardize Definitions: Develop clear definitions for different types and grades of cardiotoxicity-Biomarkers and Imaging: Standardize the use of biomarkers and imaging techniques for assessing cardiotoxicity in oncology trials-Functional Measures: Define consistent criteria for evaluating cardiac function-Monitoring Plan: Develop a standardized cardiotoxicity monitoring plan that specifies the timing of cardiac assessments during the trial.-Risk Stratification: Use a risk stratification model to identify patients at higher risk for cardiotoxicity based on pre-existing conditions and treatment regimens.-Electronic Health Records and Real-World Data: Utilize electronic health records to standardize and systematically…
Read the full description
The goal of this funding opportunity announcement is to support applied regulatory science research to evaluate and treat cardiotoxicity of oncology therapeutics. The main outcomes of this work will be publications and presentations; however, FDA staff anticipate substantial involvement in study design and reviewing interim deliverables to ensure that the studies develop practical approaches and solutions that have the potential to inform regulatory decision making in the future. We anticipate organizing regular calls with funded investigators to support the collaboration with FDA - reviewing annual reports would be insufficient to ensure that direction of the research addresses FDA's needs.OCE is interested in supporting research that improve the detection, monitoring and treatment of cardiotoxicity of oncology therapeutics.Specific areas of interest include:-Standardize Definitions: Develop clear definitions for different types and grades of cardiotoxicity-Biomarkers and Imaging: Standardize the use of biomarkers and imaging techniques for assessing cardiotoxicity in oncology trials-Functional Measures: Define consistent criteria for evaluating cardiac function-Monitoring Plan: Develop a standardized cardiotoxicity monitoring plan that specifies the timing of cardiac assessments during the trial.-Risk Stratification: Use a risk stratification model to identify patients at higher risk for cardiotoxicity based on pre-existing conditions and treatment regimens.-Electronic Health Records and Real-World Data: Utilize electronic health records to standardize and systematically collect and store cardiotoxicity data, ensuring data accuracy and completeness.-Patient-Reported Outcomes: Integrate patient-reported outcomes related to cardiovascular health (e.g., symptoms of heart failure, quality of life).-Collaborative Networks: Engage in collaborative networks with other research institutions and industry partners to share data, best practices, and insights.-Public Databases: Contribute to and utilize public databases of cardiotoxicity data to enhance the generalizability of findings and support broader research efforts.-Treatment: Develop innovative approaches to treat cardiotoxicities with new oncology therapeutics.-Natural history: Studies to investigate the natural history of various cardiotoxicities with new oncology therapeutics.
Agency contact
Terrin Brown Grantor
terrin.brown@fda.hhs.gov